Focus: Tivic is a public bioelectronics company focused on non-invasive microcurrent and bioelectronic devices for sinus and inflammatory conditions. The company operates at a modest scale with minimal revenue and cash burn exceeding $8M annually.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
Stable — net -1 jobs in 30d
0 added, 1 removed. Backfill posture.
Tivic represents a high-risk, high-reward early-stage bet on bioelectronics technology with acute near-term financial vulnerability—suitable only for risk-tolerant candidates seeking moonshot upside or those with severance runway.
Consumer-facing microcurrent device with single registered trial; revenue and market adoption unclear.
Help build intelligence for Tivic
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Tivic's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Bioelectronics device targeting inflammatory sinus indications; regulatory status and clinical validation pending.
Transcutaneous electrical nerve stimulation approach for chronic rhinosinusitis with one registered trial.
Tivic Health Systems Rebrands to Valion Bio - Contract Pharma
Tivic Health Systems Rebrands to Valion Bio Contract Pharma
Tivic Health rebrands as Valion Bio, doubles down on entolimod strategy - The Pharma Letter
Tivic Health rebrands as Valion Bio, doubles down on entolimod strategy The Pharma Letter
Valion Bio (Nasdaq: TIVC) pivots to late-stage biopharma with Entolimod and CDMO - Stock Titan
Valion Bio (Nasdaq: TIVC) pivots to late-stage biopharma with Entolimod and CDMO Stock Titan
Tivic rebrands as Valion Bio, centering Entolimod and CDMO unit - Stock Titan
Tivic rebrands as Valion Bio, centering Entolimod and CDMO unit Stock Titan
Tivic Health Selected to Present Entolimod™ as a Radiation Countermeasure and its Plans for an Oral Transmucosal Program to the Department of War Tech Watch Program on May 7th - PR Newswire
Tivic Health Selected to Present Entolimod™ as a Radiation Countermeasure and its Plans for an Oral Transmucosal Program to the Department of War Tech Watch Program on May 7th PR Newswire
Tivic CEO To Present at the Upcoming Emerging Growth's April 2026 Virtual Conference - ACCESS Newswire
Tivic CEO To Present at the Upcoming Emerging Growth's April 2026 Virtual Conference ACCESS Newswire
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Correction to: Prospective trial examining safety and efficacy of microcurrent stimulation for the treatment of sinus pain and congestion.
Prospective trial examining safety and efficacy of microcurrent stimulation for the treatment of sinus pain and congestion.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo